Royalty Pharma PLC (NASDAQ:RPRX) Increases Dividend to $0.24 Per Share

Royalty Pharma PLC (NASDAQ:RPRX) declared a quarterly dividend on Friday, January 9th. Shareholders of record on Friday, February 20th will be paid a dividend of 0.235 per share by the biopharmaceutical company on Tuesday, March 10th. This represents a c) dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, February 20th. This is a 6.8% increase from Royalty Pharma’s previous quarterly dividend of $0.22.

Royalty Pharma has a payout ratio of 17.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Royalty Pharma to earn $4.86 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 18.1%.

Royalty Pharma Stock Down 0.2%

Shares of RPRX opened at $40.17 on Friday. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. The firm has a market cap of $23.19 billion, a P/E ratio of 30.43, a PEG ratio of 1.93 and a beta of 0.43. The stock’s 50 day moving average is $39.19 and its two-hundred day moving average is $37.28. Royalty Pharma has a 12 month low of $27.47 and a 12 month high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. The firm had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. Analysts predict that Royalty Pharma will post 4.49 earnings per share for the current fiscal year.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.